The accumulation of CD4+CD25+Foxp3+ Tregs is one of the hallmark features of GBM, and Tregs have been the predominant targets for immunotherapy in glioma models and patients.28, 29. This evidence concerns the gene FOXP3 and central nervous system cancer.